<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id>
      <journal-id journal-id-type="publisher-id">YMJ</journal-id>
      <journal-title-group>
        <journal-title>Yonsei Medical Journal</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0513-5796</issn>
      <issn pub-type="epub">1976-2437</issn>
      <publisher>
        <publisher-name>Yonsei University College of Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18306483</article-id>
      <article-id pub-id-type="pmc">2615269</article-id>
      <article-id pub-id-type="doi">10.3349/ymj.2008.49.1.155</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rituximab-CHOP Induced Interstitial Pneumonitis in Patients with Disseminated Extranodal Marginal Zone B Cell Lymphoma</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Kwang Min</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Ho-Cheol</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jeon</surname>
            <given-names>Kyung-Nyeo</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Hoon-Gu</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kang</surname>
            <given-names>Jung Hun</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hahm</surname>
            <given-names>Jong Ryeal</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Lee</surname>
            <given-names>Gyeong-Won</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A3">3</xref>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea.</aff>
      <aff id="A2"><label>2</label>Department of Diagnostic Radiology, College of Medicine, Gyeongsang National University, Jinju, Korea.</aff>
      <aff id="A3"><label>3</label>Gyeongsang Institute of Health Science, Jinju, Korea.</aff>
      <aff id="A4"><label>4</label>Gyeongnam Regional Cancer Center, Jinju, Korea.</aff>
      <author-notes>
        <corresp>
Reprint address: requests to Dr. Gyeong-Won Lee, Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju 660-702, Korea. Tel: 82-55-750-8066, Fax: 82-55-758-9122, <email>brightree@lycos.co.kr</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>29</day>
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>2</month>
        <year>2008</year>
      </pub-date>
      <volume>49</volume>
      <issue>1</issue>
      <fpage>155</fpage>
      <lpage>158</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>7</month>
          <year>2006</year>
        </date>
        <date date-type="accepted">
          <day>02</day>
          <month>10</month>
          <year>2006</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2008 The Yonsei University College of Medicine</copyright-statement>
        <copyright-year>2008</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow with high LDH. Shortness of breath developed following the 5th course of Rituximab-CHOP chemotherapy (cyclophosphamide, Vincristine, Doxorubicin, Prednisolone). Bronchoscopy guided transbronchial lung biopsy revealed interstitial thickening and type II pneumocyte activation, compatible with interstitial pneumonitis. After treatment with prednisolone a complete resolution of the dyspnea was observed. The patient was well on routine follow-up at the outpatient clinic, with no progression of lymphoma or interstitial pneumonitis.</p>
      </abstract>
      <kwd-group>
        <kwd>Interstitial pneumonitis</kwd>
        <kwd>rituximab</kwd>
        <kwd>lymphoma</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Rituximab, a chimeric anti-CD20 IgG1 monoclonal antibody, is an effective treatment for B-cell low grade lymphomas. This includes extranodal marginal zone B cell lymphoma,<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref> diffuse large B-cell lymphoma,<xref ref-type="bibr" rid="B4">4</xref> refractory idiopathic thrombocytopenic purpura,<xref ref-type="bibr" rid="B5">5</xref> and other autoimmune disorders.<xref ref-type="bibr" rid="B6">6</xref></p>
      <p>The proposed mechanism of action for this depletion includes antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis.<xref ref-type="bibr" rid="B7">7</xref></p>
      <p>Interstitial pneumonitis and bronchiolitis obliterans with organizing pneumonia<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref> have been recently reported when using rituximab alone or in combination with other medications.</p>
      <p>We report a case of interstitial pneumonitis in a patient with disseminated extranodal marginal zone B cell lymphoma after the 5th cycle of rituximab and CHOP.</p>
    </sec>
    <sec sec-type="cases">
      <title>CASE REPORT</title>
      <p>A 69-year-old male was diagnosed in February 2004 with stage IV extranodal marginal zone B cell lymphoma involving the mediastinal nodes, lung parenchyma and bone marrow.</p>
      <p>Past medical history included one vessel disease, for which the patient underwent percutaneous coronary angioplasty; diabetes mellitus, and hypercholesterolemia. Medications included glimepiride, aspirin, isosorbide dinitrate, nicoradil, and atorvastatin. None of these drugs had been taken since the diagnosis of non-Hodgkin's lymphoma.</p>
      <p>Following the 5th course of rituximab-CHOP chemotherapy the patient was admitted with neutropenic fever accompanied by generalized weakness and mucositis.</p>
      <p>Empiric broad spectrum antibiotics were started along with granulocyte-colony stimulating factor. Despite recovery of the neutrophil count, the shortness of breath was aggravated and arterial blood gas analysis revealed hypoxemia (PaO<sub>2</sub>=55).</p>
      <p>Gram stain and special stains of the sputum for acid-fast bacilli, pneumocystis carinii, and fungi were negative. Routine cultures for bacteria, fungi and mycobacteria yielded no growth. A chest X-ray showed progressive infiltrates in both lung fields. A computed tomography (CT) scan of the lung revealed bilateral patchy ground-glass opacities, suggestive of new onset interstitial pneumonitis. CT also showed a reduced primary mass in the right middle lobe, consistent with the initial primary lesion (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p>
      <p>Extrathoracic echocardiogram showed normal left ventricular contractility with unaltered ejection fraction. Cardiac enzymes were also normal. Ventilation perfusion scan showed no evidence of pulmonary artery embolism. Fiberoptic bronchoscopy revealed no evidence of endobronchial lesion. No malignant cells were found in the bronchoalveolar lavage fluid.</p>
      <p>Gram stains, special analysis and cell cultures obtained from BAL and sputum following fiberoptic bronchoscopy were negative for bacteria, acid-fast bacilli, fungi and pneumocystis carinii. Bronchoscopy guided transbronchial lung biopsy was performed, showing interstitial thickening and type II pneumocyte activation compatible with interstitial pneumonitis (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p>
      <p>The patient was treated with prednisolone, 1 mg/kg a day, for 2 weeks. The dyspnea and tachypnea gradually improved, in addition to blood oxygenation and chest X-ray. A subsequent CT scan following prednisolone treatment showed marked improvement of the multifocal patchy interstitial infiltration and ground glass opacities; as well as a reduction in the primary lymphoma lesion.</p>
      <p>After 42 days of hospitalization, the patient was discharged on a tapering prednisolone regimen. He experienced complete resolution of dyspnea and dyspnea on exertion. He was well on routine follow-up at the outpatient clinic, with no lymphoma progression or interstitial pneumonitis.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The optimal therapeutic management for patients with non-gastric extranodal marginal zone B cell lymphoma has not yet been defined. For localized disease, local treatment (either radiotherapy or surgery) will typically achieve excellent disease control.<xref ref-type="bibr" rid="B11">11</xref>-<xref ref-type="bibr" rid="B13">13</xref> When the disease is advanced or disseminated, several chemotherapeutic agents alone in combination are usually administered. These regimens include alkylating agents, anthracyclins, steroids, and purine analogs.<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B13">13</xref> Anthracylines-based chemotherapy is typically recommended in patients with histological transformation or with high tumor mass (i.e. high LDH or a mass greater than 7cm).<xref ref-type="bibr" rid="B13">13</xref></p>
      <p>The use of rituximab alone or combination with cytotoxic chemotherapeutic agents is a new treatment breakthrough in disseminated or refractory disease. This is because extranodal marginal zone B cells typically express the CD20 antigen.<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref></p>
      <p>Adverse pulmonary reactions to rituximab occur as reversible events during the first infusion in 38% of patients. In addition, severe human antibody infusion reactions, generally occurring during the first 2 hours of the first infusion, can present with hypotension or angioedema. Pulmonary involvement manifests in the form of bronchospasm, hypoxia, infiltrates and even acute respiratory distress syndrome.<xref ref-type="bibr" rid="B15">15</xref> Late occurring pulmonary toxicities after the administration of rituximab have rarely been reported.<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B18">18</xref></p>
      <p>Mechanisms leading to rituximab-induced interstitial lung disease are not yet completely elucidated. However, dysregulated cellular cytotoxicity may be related to a mechanism of delayed pulmonary toxicity.<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B19">19</xref> Cytotoxic T lymphocytes (CTL) are believed to play an important role in long term anti-tumor effects after rituximab treatment.<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B19">19</xref> Their activation ('cross-priming') appears to be induced by dendritic cells, which mature under the influence of cell-derived peptides resulting from rituximab-induced tumor destruction.<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B19">19</xref> CTL activation may produce vascular and alveolar damage. Disturbed cellular cytotoxicity can also result from the interaction of rituximab with CD 20+ T-cells,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref> or by cross-reactivity between lung and tumoral antigens with possible generation of a self reactive clone.<xref ref-type="bibr" rid="B17">17</xref></p>
      <p>Pulmonary leukostasis is associated with activation of the complement system and changes in endothelial adhesivity induced by elevated cytokine levels. This leukostasis may also contribute to the dyspnea and bronchospasm often encountered in patients with high tumor burden after treatment with rituximab.<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref></p>
      <p>The emergence of pulmonary infiltrates in patients treated with rituximab and CHOP chemotherapy remains a difficult diagnostic problem. Many differential diagnoses need to be considered, including lymphoma progression, infection, cardiogenic edema, radiation pneumonitis, pulmonary hemorrhage, and allergies.</p>
      <p>One of the major clinical challenges in these patients is ruling out opportunistic infection or lymphoma progression. The infectious etiologies of diffuse interstitial infiltrates in the lungs are multiple.<xref ref-type="bibr" rid="B25">25</xref> They include any Gram-negative or Gram-positive agents, fungi (<italic>Aspergillus</italic>, <italic>Candida</italic>), parasites (<italic>Pneumocystis carinii</italic>, <italic>Toxoplasma gondii</italic>), or viruses (<italic>Herpes simplex</italic>, <italic>Varicella zoster</italic>, <italic>Cytomegalovirus</italic>).<xref ref-type="bibr" rid="B25">25</xref></p>
      <p>Non-invasive tests and studies such as chest X-ray, CT scan, echocardiogram, pulmonary function tests, and arterial blood gas analysis can easily determine the pattern of pulmonary disease present. However, fiberoptic bronchoscopy with bronchoalveolar lavage and lung biopsy is usually necessary to eliminate infection or lymphoma progression. The exclusion of all known etiologic factors associated with pulmonary interstitial infiltrates is essential for diagnosing rituximab-induced interstitial pneumonitis.</p>
      <p>We conclude that physicians should be aware of this rare, but possible complication of interstitial pneumonitis after combination rituximab-CHOP chemotherapy.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hiddemann</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kneba</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dreyling</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schmitz</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lengfelder</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Schmits</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>3725</fpage>
          <lpage>3732</lpage>
          <pub-id pub-id-type="pmid">16123223</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kussick</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Siddiqui</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Bhuiya</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Khan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sarewitz</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease</article-title>
          <source>Eur J Cancer</source>
          <year>2004</year>
          <volume>40</volume>
          <fpage>1320</fpage>
          <lpage>1326</lpage>
          <pub-id pub-id-type="pmid">15177490</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conconi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Martinelli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Thieblemont</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ferreri</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Devizzi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Peccatori</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>2741</fpage>
          <lpage>2745</lpage>
          <pub-id pub-id-type="pmid">12842999</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coiffier</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>State-of-the-art therapeutics: diffuse large B-cell lymphoma</article-title>
          <source>J Clin Oncol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>6387</fpage>
          <lpage>6393</lpage>
          <pub-id pub-id-type="pmid">16155024</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Braendstrup</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bjerrum</surname>
              <given-names>OW</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>OJ</given-names>
            </name>
            <name>
              <surname>Jensen</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Clausen</surname>
              <given-names>NT</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>PB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura</article-title>
          <source>Am J Hematol</source>
          <year>2005</year>
          <volume>78</volume>
          <fpage>275</fpage>
          <lpage>280</lpage>
          <pub-id pub-id-type="pmid">15795920</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Higashida</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wun</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Naguwa</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Tuscano</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment</article-title>
          <source>J Rheumatol</source>
          <year>2005</year>
          <volume>32</volume>
          <fpage>2109</fpage>
          <lpage>2115</lpage>
          <pub-id pub-id-type="pmid">16265687</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maloney</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Rose</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Rituximab: mechanism of action and resistance</article-title>
          <source>Semin Oncol</source>
          <year>2002</year>
          <volume>29</volume>
          <issue>1 Suppl 2</issue>
          <fpage>2</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="pmid">11842383</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kanelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ansell</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Habermann</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Inwards</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Tuinstra</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Witzig</surname>
              <given-names>TE</given-names>
            </name>
          </person-group>
          <article-title>Rituximab toxicity in patients with peripheral blood malignant B-cell Lymphocytosis</article-title>
          <source>Leuk Lymphoma</source>
          <year>2001</year>
          <volume>42</volume>
          <fpage>1329</fpage>
          <lpage>1337</lpage>
          <pub-id pub-id-type="pmid">11911416</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Burton</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kaczmarski</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jan-Mohamed</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Interstitial pneumonitis related to rituximab therapy</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <fpage>2690</fpage>
          <lpage>2691</lpage>
          <pub-id pub-id-type="pmid">12826649</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byrd</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Morrison</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Jacobson</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hoke</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>6</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="pmid">12393429</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gospodarowicz</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Pintilie</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bezjak</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Hodgson</surname>
              <given-names>DC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stage I and II MALT lymphoma: results of treatment with radiotherapy</article-title>
          <source>Int J Radiat Oncol Biol Phys</source>
          <year>2001</year>
          <volume>50</volume>
          <fpage>1258</fpage>
          <lpage>1264</lpage>
          <pub-id pub-id-type="pmid">11483337</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schechter</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Portlock</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Yahalom</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Treatment of mucosa-asociated lymphoid tissue lymphoma of the stomach with radiation alone</article-title>
          <source>J Clin Oncol</source>
          <year>1998</year>
          <volume>16</volume>
          <fpage>1916</fpage>
          <lpage>1921</lpage>
          <pub-id pub-id-type="pmid">9586910</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thieblemont</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Clinical presentation and management of marginal zone lymphomas</article-title>
          <source>Hematology Am Soc Hematol Educ Program</source>
          <year>2005</year>
          <fpage>307</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="pmid">16304396</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Soda</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costanzo</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cantonetti</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Orlandi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bianchi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chimenti</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody</article-title>
          <source>Acta Derm Venereol</source>
          <year>2001</year>
          <volume>81</volume>
          <fpage>207</fpage>
          <lpage>208</lpage>
          <pub-id pub-id-type="pmid">11558880</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kyung</surname>
              <given-names>SY</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Bang</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Jeong</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>DB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two cases of interstitial pneumonitis caused by rituximab therapy</article-title>
          <source>Korean J Intern Med</source>
          <year>2006</year>
          <volume>21</volume>
          <fpage>183</fpage>
          <lpage>186</lpage>
          <pub-id pub-id-type="pmid">17017668</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hainsworth</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Litchy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lamb</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>GI</given-names>
            </name>
            <name>
              <surname>Scroggin</surname>
              <given-names>C</given-names>
              <suffix>Jr</suffix>
            </name>
            <name>
              <surname>Greco</surname>
              <given-names>FA</given-names>
            </name>
          </person-group>
          <article-title>First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial</article-title>
          <source>Clin Lymphoma</source>
          <year>2003</year>
          <volume>4</volume>
          <fpage>36</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">12837153</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alexandrescu</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Dutcher</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>O'Boyle</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Albulak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Oiseth</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wiernik</surname>
              <given-names>PH</given-names>
            </name>
          </person-group>
          <article-title>Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma</article-title>
          <source>Leuk Lymphoma</source>
          <year>2004</year>
          <volume>45</volume>
          <fpage>2321</fpage>
          <lpage>2325</lpage>
          <pub-id pub-id-type="pmid">15512824</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herishanu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Polliack</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Leider-Trejo</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Grieff</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Metser</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Naparstek</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Fatal interstitial pneumonitis related to rituximab-containing regimen</article-title>
          <source>Clin Lymphoma Myeloma</source>
          <year>2006</year>
          <volume>6</volume>
          <fpage>407</fpage>
          <lpage>409</lpage>
          <pub-id pub-id-type="pmid">16640819</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Selenko</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Maidic</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Draxier</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Berer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>J&#xE4;ger</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells</article-title>
          <source>Leukemia</source>
          <year>2001</year>
          <volume>5</volume>
          <fpage>1619</fpage>
          <lpage>1626</lpage>
          <pub-id pub-id-type="pmid">11587221</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hultin</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Hausner</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hultin</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Giorgi</surname>
              <given-names>JV</given-names>
            </name>
          </person-group>
          <article-title>CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes</article-title>
          <source>Cytometry</source>
          <year>1993</year>
          <volume>14</volume>
          <fpage>196</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">7679964</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Algino</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Thomason</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>King</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Montiel</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Craig</surname>
              <given-names>FE</given-names>
            </name>
          </person-group>
          <article-title>CD20 (pan-B cell antigen) expression on bone marrow-derived T cells</article-title>
          <source>Am J Clin Pathol</source>
          <year>1996</year>
          <volume>106</volume>
          <fpage>78</fpage>
          <lpage>81</lpage>
          <pub-id pub-id-type="pmid">8701937</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warzynski</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Axtell</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Zakem</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Rotman</surname>
              <given-names>RK</given-names>
            </name>
          </person-group>
          <article-title>Low level CD20 expression on T cell malignancies</article-title>
          <source>Cytometry</source>
          <year>1994</year>
          <volume>18</volume>
          <fpage>88</fpage>
          <lpage>92</lpage>
          <pub-id pub-id-type="pmid">7523045</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jensen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Winkler</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Manzke</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Diehl</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Engert</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)</article-title>
          <source>Ann Hematol</source>
          <year>1998</year>
          <volume>77</volume>
          <fpage>89</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="pmid">9760161</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Byrd</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Waselenko</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Maneatis</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ward</surname>
              <given-names>FT</given-names>
            </name>
            <name>
              <surname>Monahan</surname>
              <given-names>BP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance</article-title>
          <source>J Clin Oncol</source>
          <year>1999</year>
          <volume>17</volume>
          <fpage>791</fpage>
          <lpage>795</lpage>
          <pub-id pub-id-type="pmid">10071268</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Merad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Le Cesne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baldeyrou</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Mesurolle</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Le Chevalier</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Docetaxel and interstitial pulmonary injury</article-title>
          <source>Ann Oncol</source>
          <year>1997</year>
          <volume>8</volume>
          <fpage>191</fpage>
          <lpage>194</lpage>
          <pub-id pub-id-type="pmid">9093730</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Computed tomography of the chest, showing new bilateral patchy ground-glass opacities.</p>
      </caption>
      <graphic xlink:href="ymj-49-155-g001"/>
    </fig>
    <fig id="F2" position="float">
      <label>Fig. 2</label>
      <caption>
        <p>Transbronchial lung biopsy, showing interstitial thickening and type II pneumocyte activation (&#xD7;200, hematoxylin and eosin).</p>
      </caption>
      <graphic xlink:href="ymj-49-155-g002"/>
    </fig>
  </floats-group>
</article>
</pmc-articleset>
